Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.5 - $2.66 $18,393 - $97,853
-36,787 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$1.87 - $4.77 $68,791 - $175,473
36,787 New
36,787 $85,000
Q4 2019

Feb 14, 2020

SELL
$7.23 - $8.55 $77,389 - $91,519
-10,704 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$6.42 - $9.0 $65,760 - $92,187
-10,243 Reduced 48.9%
10,704 $82,000
Q2 2019

Aug 14, 2019

SELL
$6.1 - $8.78 $44,835 - $64,532
-7,350 Reduced 25.97%
20,947 $143,000
Q3 2018

Nov 15, 2018

BUY
$8.24 - $11.0 $69,018 - $92,136
8,376 Added 42.05%
28,297 $271,000
Q2 2018

Aug 14, 2018

BUY
$7.87 - $10.89 $156,778 - $216,939
19,921 New
19,921 $211,000

Others Institutions Holding AGLE

# of Institutions
1
Shares Held
241K
Call Options Held
0
Put Options Held
0

About Aeglea BioTherapeutics, Inc.


  • Ticker AGLE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,172,500
  • Market Cap $1.69B
  • Description
  • Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...
More about AGLE
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.